OAT-3912

OAT-3912 is a first-in-class, small molecule inhibitor that selectively targets YKL-40 (also known as chitinase 3-like protein 1, CHI3L1). Developed by Molecure and licensed to Ocean Biomedical for further development and commercialization, OAT-3912 has demonstrated efficacy in preclinical models of cancer as well as inflammatory and fibrotic diseases. The compound works by strongly and selectively binding to YKL-40, a protein implicated in tumor progression, inflammation, and fibrosis. By inhibiting YKL-40 activity, OAT-3912 offers a novel therapeutic approach for conditions with high unmet medical need[3][7][9].